We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Read MoreHide Full Article
Key Takeaways
Veeva raised FY27 revenue guidance to $3.682-$3.687B, implying about 15% growth at the high end.
VEEV's Vault CRM now has commitments from 12 of the top 20 biopharma firms, with 180 customers live.
Veeva's Falcon AI has five early adopters, but product execution remain key near-term priorities.
Veeva Systems Inc. (VEEV - Free Report) raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million. Vault CRM adoption and broader commercial execution added another positive signal.
The question is how quickly CRM migrations, newer R&D products and Falcon can extend growth without raising execution risk. Veeva’s guidance points to continued profitability, but several newer initiatives are still early.
VEEV Raises Its Fiscal 2027 Financial Targets
Veeva now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion and adjusted earnings of roughly $9.21 per share. The revenue outlook implies about 15% growth at the high end.
Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. That combination keeps profitability intact while the company continues investing in product development and artificial intelligence.
Image Source: Zacks Investment Research
Veeva’s Vault CRM Migration Reaches New Milestones
Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections. Veeva now has commitments from 12 of the top 20, while more than 180 customers are already live on Vault CRM.
The migration can also deepen adoption across Veeva’s Commercial Cloud. Salesforce, Inc. (CRM - Free Report) , which competes in CRM and agentic software, reported second-quarter fiscal 2027 revenues of $11.3 billion, up 11% year over year, underscoring the scale of enterprise CRM and AI competition.
VEEV’s Falcon AI Adds a New Growth Avenue
Falcon moves Veeva into agentic labor for workflows such as clinical document processing and safety case intake. Five customers are early adopters, including a top-20 pharma company, and first go-lives are expected in 2026.
Customer interest is running ahead of product readiness. Management said Veeva is currently the rate limiter as it works to prove agent quality, operating processes and human-review controls, making execution more important than near-term Falcon revenues.
Veeva’s R&D Portfolio Broadens the Growth Base
Veeva’s R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter. Management expects newer products, including EDC, eCOA, RTSM, Safety and LIMS, to become more important as mature applications grow more slowly.
IQVIA Holdings Inc. (IQV - Free Report) provides another life-sciences technology comparison. Its second-quarter 2026 revenues rose 8.7% to $4.37 billion, with both Commercial Solutions and R&D Solutions expanding, highlighting continued spending across life-sciences data, technology and research workflows.
Image Source: Zacks Investment Research
VEEV Must Convert Innovation Into Durable Growth
The guidance increase and product progress raise the execution bar. Continued CRM migrations must translate into successful deployments and broader Commercial Cloud adoption, while the newer R&D applications need to offset slower growth in established products.
Falcon adds another layer of opportunity, but monetization remains early. Pricing is still being developed and management is not relying on material near-term Falcon revenues, so product readiness and customer outcomes will be key indicators of progress.
VEEV’s Style Scores Reflect the Mixed Setup
The investment setup remains balanced. Veeva is delivering mid-teens growth, high adjusted operating profitability and broader product momentum, but Vault CRM migrations and newer AI and R&D products still require sustained execution.
VEEV currently carries a Zacks Rank #3 (Hold), with a Value Score of D, a Growth Score of B, a Momentum Score of A and a VGM Score of B. The favorable Growth and Momentum Scores support the company’s operating and share-price trends, while the weaker Value Score tempers the setup. The Hold rank and B VGM Score point to a measured near-term view rather than a clear-cut directional signal.
View the Zacks #1 Rank List
Image: Bigstock
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Key Takeaways
Veeva Systems Inc. (VEEV - Free Report) raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million. Vault CRM adoption and broader commercial execution added another positive signal.
The question is how quickly CRM migrations, newer R&D products and Falcon can extend growth without raising execution risk. Veeva’s guidance points to continued profitability, but several newer initiatives are still early.
VEEV Raises Its Fiscal 2027 Financial Targets
Veeva now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion and adjusted earnings of roughly $9.21 per share. The revenue outlook implies about 15% growth at the high end.
Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. That combination keeps profitability intact while the company continues investing in product development and artificial intelligence.
Image Source: Zacks Investment Research
Veeva’s Vault CRM Migration Reaches New Milestones
Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections. Veeva now has commitments from 12 of the top 20, while more than 180 customers are already live on Vault CRM.
The migration can also deepen adoption across Veeva’s Commercial Cloud. Salesforce, Inc. (CRM - Free Report) , which competes in CRM and agentic software, reported second-quarter fiscal 2027 revenues of $11.3 billion, up 11% year over year, underscoring the scale of enterprise CRM and AI competition.
VEEV’s Falcon AI Adds a New Growth Avenue
Falcon moves Veeva into agentic labor for workflows such as clinical document processing and safety case intake. Five customers are early adopters, including a top-20 pharma company, and first go-lives are expected in 2026.
Customer interest is running ahead of product readiness. Management said Veeva is currently the rate limiter as it works to prove agent quality, operating processes and human-review controls, making execution more important than near-term Falcon revenues.
Veeva’s R&D Portfolio Broadens the Growth Base
Veeva’s R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter. Management expects newer products, including EDC, eCOA, RTSM, Safety and LIMS, to become more important as mature applications grow more slowly.
IQVIA Holdings Inc. (IQV - Free Report) provides another life-sciences technology comparison. Its second-quarter 2026 revenues rose 8.7% to $4.37 billion, with both Commercial Solutions and R&D Solutions expanding, highlighting continued spending across life-sciences data, technology and research workflows.
Image Source: Zacks Investment Research
VEEV Must Convert Innovation Into Durable Growth
The guidance increase and product progress raise the execution bar. Continued CRM migrations must translate into successful deployments and broader Commercial Cloud adoption, while the newer R&D applications need to offset slower growth in established products.
Falcon adds another layer of opportunity, but monetization remains early. Pricing is still being developed and management is not relying on material near-term Falcon revenues, so product readiness and customer outcomes will be key indicators of progress.
VEEV’s Style Scores Reflect the Mixed Setup
The investment setup remains balanced. Veeva is delivering mid-teens growth, high adjusted operating profitability and broader product momentum, but Vault CRM migrations and newer AI and R&D products still require sustained execution.
VEEV currently carries a Zacks Rank #3 (Hold), with a Value Score of D, a Growth Score of B, a Momentum Score of A and a VGM Score of B. The favorable Growth and Momentum Scores support the company’s operating and share-price trends, while the weaker Value Score tempers the setup. The Hold rank and B VGM Score point to a measured near-term view rather than a clear-cut directional signal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.